Handelsavisen
prelaunch
Companies ›Healthcare ›206650.KQ
20
206650.KQ — KOSDAQ Pharmaceuticals

EuBiologics Co Ltd

$10 790,00
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
15,6 %
ROE
-3,3 %
Net margin
-23,8 %
Debt / equity
0,13
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

EuBiologics Co Ltd is a South Korean biopharmaceutical company focused on the development and commercialization of biosimilars and biologics, primarily targeting the domestic and international markets.

Business. EuBiologics Co Ltd (206650.KQ) is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm operates within the Healthcare sector, specifically focusing on product sales within the pharmaceutical industry. Headquarters and specific operating segment details are not provided in the available data. The company is primarily listed on the KOSDAQ exchange.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryPharmaceuticals
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
BUY1 analysts
1 buy0 hold0 sell
Avg 12m price target19 000,00

Analyst recommendations

1 analysts · consensus Buy
Buy1
Hold0
Sell0
12-month price target
19 000,00
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts→
Buy
1 analysts · indicative
Ownership
—
not yet wired
Profitability→
-3,3 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 206650.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 206650.KQ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    EuBiologics Co Ltd (206650.KQ) is a pharmaceutical company engaged in pharmaceuticals and medical research. The firm operates within the Healthcare sector, specifically focusing on product sales within the pharmaceutical industry. Headquarters and specific operating segment details are not provided in the available data. The company is primarily listed on the KOSDAQ exchange.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryPharmaceuticals
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    ### Capital Structure and Liquidity EuBiologics maintains a strong liquidity position with $1.45 billion in cash and equivalents, representing 9.4% of total assets. The company's current ratio of 1.81 indicates a solid short-term liquidity buffer, while its debt-to-equity ratio of 0.13 suggests a conservative capital structure with limited leverage. Despite a negative net income of $361.5 million, the firm generated $708.5 million in operating cash flow, highlighting operational resilience.

    ### Profitability and Returns The company's profitability metrics are mixed. Gross profit of $768.2 million reflects a 50.6% margin, but net income is negative at -$361.5 million, resulting in a return on equity of -3.34% and a return on assets of -2.33%. These figures fall below the industry median for ROE and ROA in the biotechnology sector, indicating underperformance relative to peers.

    ### Segments and Geographic Exposure EuBiologics operates as a single business segment focused on biosimilars and biologics. Revenue is concentrated in South Korea, with no material geographic diversification disclosed. The company's reliance on a single market increases exposure to regulatory and economic shifts in the region.

    ### Growth Trajectory Recent financial data shows a revenue of $1.52 billion, but the company has not disclosed segment-level growth rates. Analysts have assigned a mean price target of 19,000 KRW, with a strong buy recommendation, though no specific revenue growth projections are provided in the input data.

    ### Risk Factors The company faces moderate liquidity risk due to its negative net income and free cash flow of -$352.5 million. However, the risk assessment indicates low dilution risk, with no immediate filing-based flags detected. The firm's capital expenditure of -$2.08 billion suggests significant investment in long-term assets, which could impact short-term liquidity.

    ### Recent Events No recent filings or transcripts are provided in the input data to assess material events or strategic shifts. The company's financial performance and operational strategy remain largely unchanged based on the latest available data.

    Key takeaways
    • EuBiologics maintains a strong liquidity position with $1.45 billion in cash and a current ratio of 1.81.
    • The company's return on equity of -3.34% and return on assets of -2.33% indicate underperformance relative to industry peers.
    • Revenue is concentrated in South Korea, increasing exposure to regional regulatory and economic risks.
    • Analysts have assigned a strong buy rating with a mean price target of 19,000 KRW, but no specific growth projections are provided.
    • The firm's capital expenditure of -$2.08 billion suggests significant investment in long-term assets.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 4

    Analysts project 76.1% upside to a 19,000 target price, reflecting strong buy consensus on future growth potential.

    Low dilution, liquidity, and credit risk flags suggest a stable financial structure with minimal immediate downside threats.

    Debt-to-equity ratio of 0.13 is below the cohort median of 0.18, indicating a conservative leverage position.

    Recent fiscal year revenue reached 149 billion, showing substantial scale despite historical volatility in profitability metrics.

    BEAR CASE · 3

    Cash conversion ratio of -1.96 is in the bottom quartile, highlighting severe challenges in generating cash from operations.

    Revenue CAGR of -7.8% over four years indicates a long-term decline in top-line growth momentum.

    Net income volatility is extreme, with a -1163% year-over-year change, demonstrating unstable earnings performance.

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-02-02
    Q4 2025 · Quarter highlights

    Revenue UNKNOWN ERROR IN UNIVERSE PROCESSING 32.33B, −12,2% YoY; Operating income +37,3% YoY.

    RevenueUNKNOWN ERROR IN UNIVERSE PROCESSING 32.33B−12,2 % YoY
    Operating incomeUNKNOWN ERROR IN UNIVERSE PROCESSING 11.04B+37,3 % YoY
    Net incomeUNKNOWN ERROR IN UNIVERSE PROCESSING 414.0M−95,0 % YoY
    Free cash flow-UNKNOWN ERROR IN UNIVERSE PROCESSING 4.76B−139,2 % YoY
    EPS—
    Operating cash flowUNKNOWN ERROR IN UNIVERSE PROCESSING 49.10B+13,6 % YoY
    Financials
    Income statement
    RevenueUNKNOWN ERROR IN UNIVERSE PROCESSING 32.33B
    Gross profitUNKNOWN ERROR IN UNIVERSE PROCESSING 21.49B
    Operating incomeUNKNOWN ERROR IN UNIVERSE PROCESSING 11.04B
    Net incomeUNKNOWN ERROR IN UNIVERSE PROCESSING 414.0M
    Margins
    Gross margin66.5%
    Operating margin34.1%
    Net margin1.3%
    FCF margin-14.7%
    Balance sheet
    Total assetsUNKNOWN ERROR IN UNIVERSE PROCESSING 240.23B
    Total liabilitiesUNKNOWN ERROR IN UNIVERSE PROCESSING 64.87B
    Total equityUNKNOWN ERROR IN UNIVERSE PROCESSING 175.36B
    Cash & equivalentsUNKNOWN ERROR IN UNIVERSE PROCESSING 16.59B
    Long-term debtUNKNOWN ERROR IN UNIVERSE PROCESSING 4.00B
    Cash flow
    Operating cash flowUNKNOWN ERROR IN UNIVERSE PROCESSING 49.10B
    CapEx-UNKNOWN ERROR IN UNIVERSE PROCESSING 16.96B
    Free cash flow-UNKNOWN ERROR IN UNIVERSE PROCESSING 4.76B
    SBC—
    P&L flow · revenue → net income
    Revenue UNKNOWN ERROR IN UNIVERSE PROCESSING 32.33BOperating costs UNKNOWN ERROR IN UNIVERSE PROCESSING 21.29BTax UNKNOWN ERROR IN UNIVERSE PROCESSING 10.63BNet income UNKNOWN ERROR IN UNIVERSE PROCESSING 414.0M
    Highlights
    • ▍Revenue UNKNOWN ERROR IN UNIVERSE PROCESSING 32.33B, −12,2% YoY
    • ▍Operating income +37,3% YoY
    • ▍Net income −95,0% YoY
    • ▍Free cash flow −139,2% YoY
    • ▍Net margin 1.3%

    Valuation TTM

    Market price
    $10 790,00
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    $108.29B
    Net cashⓘ
    $534.8M
    Current ratioⓘ
    1.8
    Debt / equityⓘ
    0.1
    ROAⓘ
    -2.3%
    ROEⓘ
    -3.3%
    Cash conversionⓘ
    -196.0%
    CapEx / revenueⓘ
    -13.7%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    1 050,00
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    1
    Other metrics
    Revenue
    —
    no estimate
    Segment revenue
    —
    no estimate
    Margin
    —
    no estimate
    Segment margin
    —
    no estimate
    as of 2026-05-07 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPS—no estimate—no estimate1 050,00
    Revenue—no estimate—no estimate139,3B KRW
    Operating income—no estimate—no estimate47,1B KRW
    Full-year consensus mean (period as reported by source) · consensus in KRW. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution1 analysts
    Strong buy1
    Buy0
    Hold0
    Sell0
    Strong sell0
    12-month price target$19 000,00 · Median $19 000,00
    Low $19 000,00High $19 000,00
    Operating income · consensus47,1B KRW
    EPS surprise
    +7,1 %
    reported vs consensus · beat
    Revenue surprise
    +7,1 %
    reported vs consensus · beat

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$19 000,00
    Mean$19 000,00
    Median$19 000,00
    High$19 000,00
    Spot$10 790,00
    +76.1 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin15,6 %Above P75
    Net Margin-23,8 %Bottom quartile
    ROE-3,3 %Below median
    Capex / Rev-13,7 %Below median
    D/E0,13Above median
    Cash Conv-1,96Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • EuBiologics Co Ltd Market data — financials · 2026-05-26
    • EuBiologics Co Ltd Market data — analyst estimates · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    206650.KQCanonical
    KOSDAQ · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-02-02 13:03 UTCEARNINGSQuarterly results — Q4 2025 Revenue Unknown error in universe processing 32.33B · Net Unknown error in universe processing 414.0M
    2026-02-02 13:03 UTCEARNINGSAnnual results — FY 2026 Revenue Unknown error in universe processing 149.20B · Net Unknown error in universe processing 41.26B
    2025-11-10 13:40 UTCEARNINGSQuarterly results — Q3 2025 Revenue Unknown error in universe processing 41.12B · Net Unknown error in universe processing 17.43B
    2025-08-13 13:24 UTCEARNINGSQuarterly results — Q2 2025 Revenue Unknown error in universe processing 36.23B · Net Unknown error in universe processing 7.73B
    2025-05-13 12:28 UTCEARNINGSQuarterly results — Q1 2025 Revenue Unknown error in universe processing 39.51B · Net Unknown error in universe processing 15.70B
    2025-02-03 11:03 UTCEARNINGSQuarterly results — Q4 2024 Revenue Unknown error in universe processing 36.83B · Net Unknown error in universe processing 8.23B
    2025-02-03 11:03 UTCEARNINGSAnnual results — FY 2025 Revenue Unknown error in universe processing 96.04B · Net Unknown error in universe processing 19.12B
    2024-10-28 12:57 UTCEARNINGSQuarterly results — Q3 2024 Revenue Unknown error in universe processing 36.15B · Net Unknown error in universe processing 16.09B
    2024-08-13 13:07 UTCEARNINGSQuarterly results — Q2 2024 Revenue Unknown error in universe processing 7.87B · Net Unknown error in universe processing -1.59B
    2024-05-13 22:39 UTCEARNINGSQuarterly results — Q1 2024 Revenue Unknown error in universe processing 15.19B · Net Unknown error in universe processing -3.62B
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage